Neumora Extends Cash Runway to Q3 2027, Key MDD Trial Data Expected Q2
summarizeSummary
Neumora Therapeutics reported its first-quarter 2026 financial results and provided a comprehensive business update, highlighting an extended cash runway and significant pipeline progress. The company now expects its $147.1 million in cash and equivalents to fund operations into the third quarter of 2027, a material extension from previous guidance. Financially, Neumora also reported a reduced net loss of $53.5 million for the quarter, down from $68.0 million in the prior year. Critically, the company announced that its pivotal KOASTAL-2 and -3 studies for navacaprant in major depressive disorder are fully enrolled and on track for a joint topline readout in the second quarter of 2026, representing a major near-term catalyst. Additionally, positive Phase 1b data for NMRA-511 in Alzheimer's disease agitation was reported, with further data expected in the second half of 2026. Traders will be closely watching the upcoming navacaprant data, which could significantly impact the company's valuation.
At the time of this announcement, NMRA was trading at $2.39 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $425.7M. The 52-week trading range was $0.61 to $3.65. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.